Dato-DXd +/- Durvalumab vs. Investigator's choice in Triple Neg Breast Ca

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

For More Information:

https://clinicaltrials.gov/study/NCT05629585?term=A%20Phase%203%20Open-label,%20Randomised%20Study%20of%20Datopotamab%20Deruxtecan%20(Dato-DXd)%20With%20or%20Without%20Durvalumab%20Versus%20Investigator%27s%20Choice%20of%20Therapy%20in%20Patients%20With%20Stage%20I-III%20Triple-negative%20Breast%20Cancer%20Who%20Have%20Residual%20Invasive%20Disease%20in%20the%20Breast%20and%2For%20Axillary%20Lymph%20Nodes%20at%20Surgical%20Resection%20Following%20Neoadjuvant%20Systemic%20Therapy%20(TROPION-Breast03)(D926XC00001)&rank=1